MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
convertible notes payable -...
$225,000
Proceeds from issuance of
convertible notes payable
$110,000
Proceeds from issuance of
common stock of...
$75,000
Net cash provided by
financing activities
$329,872
Effect of exchange
rates on cash and...
$285
Canceled cashflow
$80,128
Net decrease in cash
and restricted cash
-$27,408
Canceled cashflow
$330,157
Other accrued
expenses
$406,932
Stock-based compensation
$306,051
Accounts payable
$99,095
Prepaid expenses and
other current assets
-$80,081
Accrued interest
$50,422
Non-cash operating lease
expense
$11,967
Depreciation
$466
Repayment of short-term
notes payable
$80,128
Net cash used in
operating activities
-$357,565
Canceled cashflow
$955,014
Net loss
-$1,300,949
Operating lease liability
-$11,630
Back
Back
Cash Flow
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
source: myfinsight.com